Loading patent…
AssigneeSorrento Therapeutics, Inc.
InventorsHeyue Zhou, Randy Gastwirt, Barbara A. Swanson, John Dixon Gray, Gunnar F. Kaufmann
Estimating the term…
There is disclosed compositions and methods relating to or derived from anti-PD-L1 antibodies. More specifically, there is disclosed fully human antibodies that bind PD-L1, PD-L1-binding fragments and derivatives of such antibodies, and PD-L1-binding polypeptides comprising such fragments. Further still, there is disclosed nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating or diagnosing subjects having PD-L1 related disorders or conditions, including various inflammatory disorders and various cancers.
A recombinant fully human antibody of an IgG class that binds to a PD-L1 epitope, wherein the antibody comprises:
A fully human antibody Fab fragment that binds to a PD-L1 epitope, wherein the Fab fragment comprises a heavy chain variable domain comprising an amino acid sequence that is at least 95% identical to the amino acid sequence of and a light chain variable domain comprising an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO. 148.
A single chain human antibody that binds to a PD-L1 epitope, wherein the single chain human antibody comprises a heavy chain variable domain, a light chain variable domain and a peptide linker connecting the heavy chain variable domain and light chain variable domain wherein the heavy chain variable domain comprises an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO. 147, and the light chain variable domain comprises an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO. 148.
(canceled)
-11. (canceled)
A recombinant fully human anti-PD-L1 antibody, or an antigen-binding fragment thereof, comprising a heavy chain variable domain comprising complementarity determining regions (CDRs) as set forth in the heavy chain variable domain amino acid sequence of SEQ ID NO:
Dependencies are inferred from the claim text.